Search: onr:"swepub:oai:DiVA.org:uu-14706" >
Genome-wide pharmac...
-
Kindmark, AndreasUppsala universitet,Institutionen för medicinska vetenskaper,Metabolic Bone Diseases
(author)
Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis
- Article/chapterEnglish2008
Publisher, publication year, extent ...
-
2007-05-15
-
Springer Science and Business Media LLC,2008
-
printrdacarrier
Numbers
-
LIBRIS-ID:oai:DiVA.org:uu-14706
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-14706URI
-
https://doi.org/10.1038/sj.tpj.6500458DOI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:117069271URI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
One of the major goals of pharmacogenetics is to elucidate mechanisms and identify patients at increased risk of adverse events (AEs). To date, however, there have been only a few successful examples of this type of approach. In this paper, we describe a retrospective case–control pharmacogenetic study of an AE of unknown mechanism, characterized by elevated levels of serum alanine aminotransferase (ALAT) during long-term treatment with the oral direct thrombin inhibitor ximelagatran. The study was based on 74 cases and 130 treated controls and included both a genome-wide tag single nucleotide polymorphism and large-scale candidate gene analysis. A strong genetic association between elevated ALAT and the MHC alleles DRB1*07 and DQA1*02 was discovered and replicated, suggesting a possible immune pathogenesis. Consistent with this hypothesis, immunological studies suggest that ximelagatran may have the ability to act as a contact sensitizer, and hence be able to stimulate an adaptive immune response.
Subject headings and genre
-
pharmacogenetics
-
pharmacogenomics
-
adverse event
-
immune system
-
liver injury
-
MEDICINE
-
MEDICIN
Added entries (persons, corporate bodies, meetings, titles ...)
-
Jawaid, A
(author)
-
Harbron, C G
(author)
-
Barratt, B J
(author)
-
Bengtsson, O F
(author)
-
Andersson, T BKarolinska Institutet
(author)
-
Carlsson, S
(author)
-
Cederbrant, K E
(author)
-
Gibson, N J
(author)
-
Armstrong, M
(author)
-
Lagerström-Fermér, M E
(author)
-
Dellsén, A
(author)
-
Brown, E M
(author)
-
Thornton, M
(author)
-
Dukes, C
(author)
-
Jenkins, S C
(author)
-
Firth, M A
(author)
-
Harrod, G O
(author)
-
Pinel, T H
(author)
-
Billing-Clason, S M E
(author)
-
Cardon, L R
(author)
-
March, R E
(author)
-
Uppsala universitetInstitutionen för medicinska vetenskaper
(creator_code:org_t)
Related titles
-
In:The Pharmacogenomics Journal: Springer Science and Business Media LLC8:3, s. 186-1951470-269X1473-1150
Internet link
Find in a library
To the university's database
- By the author/editor
-
Kindmark, Andrea ...
-
Jawaid, A
-
Harbron, C G
-
Barratt, B J
-
Bengtsson, O F
-
Andersson, T B
-
show more...
-
Carlsson, S
-
Cederbrant, K E
-
Gibson, N J
-
Armstrong, M
-
Lagerström-Fermé ...
-
Dellsén, A
-
Brown, E M
-
Thornton, M
-
Dukes, C
-
Jenkins, S C
-
Firth, M A
-
Harrod, G O
-
Pinel, T H
-
Billing-Clason, ...
-
Cardon, L R
-
March, R E
-
show less...
- Articles in the publication
-
The Pharmacogeno ...
- By the university
-
Uppsala University
-
Karolinska Institutet